[The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].

Title[The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
Publication TypeJournal Article
Year of Publication2013
AuthorsPan C-Y, Ji L-N, Lu J-M, Yang W-Y, Zhou Z-G, Zou D-J, Ji Q-H, Han P, Liu J, Li Q, Su B-L, Li Y-B, Gao Z-N, Wang P-H, Yin S-N, Dong Y-H, Yang T, Sun K, Li H, Hong X, Lin J, Shi J-M, Yang X-J, Fang H, Yan X-D
Corporate AuthorsSOLVE™ Chinese study group
JournalZhonghua nei ke za zhi [Chinese journal of internal medicine]
Volume52
Issue1
Pagination11-5
Date Published2013 Jan
Abstract

Study of Once-daily LeVEmir(®) (SOLVE(TM)) was a 24-week international observational study to evaluate the safety and effectiveness of initiating once-daily insulin detemir (Levemir) as add-on therapy in patients with type 2 diabetes mellitus (T2DM) who failed treatment of oral anti-diabetic drugs (OAD).

DOI10.1111/cea.12093
Alternate JournalZhonghua Nei Ke Za Zhi